Evolus Announces Participation in September Investment Conferences

Rhea-AI Summary

Evolus, Inc. (NASDAQ: EOLS) announces participation in two investment conferences this September. The first event is the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, available on-demand from 7:00am ET. The second is the Cantor 2021 Virtual Global Healthcare Conference on September 28 at 3:20pm ET. Both webcasts will be accessible on Evolus' investor relations website for 90 days post-presentation. Evolus is known for its innovative beauty products, including Jeuveau®, the first neurotoxin dedicated to aesthetics, approved by the FDA in 2019.

Positive

• Participation in two significant investment conferences could enhance investor engagement and awareness.
• Evolus' unique product Jeuveau® positions it advantageously in the growing aesthetics market.

Negative

• None.

NEWPORT BEACH, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of management will be participating in two investment conferences in September.

Event:	H.C. Wainwright 23rd Annual Global Investment Conference
Date:	Monday, September 13, 2021
Time:	Available on-demand starting at 7:00am ET
Event:	Cantor 2021 Virtual Global Healthcare Conference
Date:	Tuesday, September 28, 2021
Time:	3:20pm ET

Audio webcasts of these events will be available on the investor relations section of Evolus’ website at www.evolus.com. Replays of the webcasts will be available for 90 days after the date of each presentation.

About Evolus, Inc.

Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. Approved in 2019 by the U.S. Food and Drug Administration, Jeuveau® (prabotulinumtoxinA-xvfs) is the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus’ unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at www.evolus.com.

Jeuveau^® is a registered trademark of Evolus, Inc.

Hi-Pure^™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

Evolus, Inc. Contacts:

Investor Contact:
David K. Erickson, Evolus, Inc.
Vice President, Investor Relations
Tel: 949-966-1798
Email: david.erickson@evolus.com

Media Contact:
Crystal Muilenburg, Evolus, Inc.
Chief Marketing Officer
Tel: 949-284-4506
Email: media@evolus.com

FAQ

What investment conferences is Evolus attending in September 2021?

Evolus is attending the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 and the Cantor 2021 Virtual Global Healthcare Conference on September 28.

What is the purpose of Evolus' participation in investment conferences?

The participation aims to increase investor engagement and provide updates on company performance and products.

When will the webcasts of the Evolus conferences be available?

The webcasts will be available on-demand starting September 13 and September 28, for 90 days after each event.

What product did Evolus launch in 2019?

Evolus launched Jeuveau®, the first neurotoxin exclusively dedicated to aesthetics, approved by the FDA in 2019.

What technology does Jeuveau® utilize?

Jeuveau® is manufactured using Evolus' Hi-Pure™ technology, designed to enhance customer experience in aesthetic treatments.